Compare HNRG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | OMER |
|---|---|---|
| Founded | 1949 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.5M | 844.6M |
| IPO Year | 1995 | 2008 |
| Metric | HNRG | OMER |
|---|---|---|
| Price | $14.76 | $20.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $25.38 | ★ $32.50 |
| AVG Volume (30 Days) | 611.0K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $469,466,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.12 | $233.22 |
| P/E Ratio | ★ N/A | $26.14 |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $13.65 | $4.06 |
| 52 Week High | $24.70 | $21.24 |
| Indicator | HNRG | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 62.23 |
| Support Level | $13.80 | $18.00 |
| Resistance Level | $16.97 | N/A |
| Average True Range (ATR) | 0.60 | 0.89 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 23.47 | 74.58 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.